Why Inagene
Not all pharmacogenetic programs are built the same. The difference between a test that generates a report and a program that drives measurable outcomes comes down to a chain that has to hold at every link:
The breadth of the panel
The standard of evidence behind it
The safety and security of the data you put in it
The quality of the lab producing it
The support built around it
We continuously monitor our security – you can too →
| Capability | Standard PGx Programs | Inagene |
|---|---|---|
| Genes analyzed | 15–25 genes | 48 genes |
| Variants covered | Limited | 123 variants |
| Medications covered | 100–150 | 240+ |
| Canadian-owned and operated lab | Varies | ✓ |
| CLIA, COLA, and CAP accredited | Varies | ✓ |
| Health Canada licensed | Varies | ✓ |
| ISO27001 certification | ✗ | ✓ |
| Evidence standard* | Varies — some use lower thresholds | Expert guidelines and standards including CPIC and others |
| Always up to date | ✗ | ✓ |
| Diverse population coverage | Limited — most panels based on limited demographics | Broad variant coverage across diverse populations |
| Pharmacist consultation included | ✗ | ✓ |
| Account management and member engagement support | ✗ | ✓ |
| Plan-level outcomes reporting | ✗ | ✓ |
*A note on evidence standards: some PGx providers include medication-gene associations at lower levels of clinical evidence, flagging interactions that are technically detectable but not yet actionable. Inagene includes only associations meeting the most rigorous thresholds, ensuring every recommendation in a member's report is clinically meaningful and defensible.
01
Inagene analyzes 48 genes and 123 variants (and growing) — more than any other pharmacogenetic test available in Canada. Standard panels are typically built on data from limited demographic populations, which means they may miss clinically significant variants in members from diverse ethnic backgrounds. Inagene’s broader coverage serves the full diversity of Canadian plan populations.
02
Inagene owns and operates a fully dedicated, Canadian PGx laboratory, independently accredited to the highest international clinical laboratory standards and licensed by Health Canada (#9922). Every sample is analyzed on Canadian soil, and all member genetic data is stored in Canadian data centres, compliant with applicable privacy laws.
Results go directly to the member and their treating clinician — never to the employer, insurer, or plan administrator. For organizations embedding a genetic testing program into their benefit plan or case management workflow, this separation is essential.
03
Inagene’s testing protocols are based on leading pharmacogenomic guidelines including CPIC, DPWG, ClinPGx, FDA, CERSI-PGx, CPNDS, and others. We only add medication-gene associations that meet the most rigorous clinical evidence thresholds which prescribers can confidently act on.
04
Pharmacogenetics is a rapidly evolving science. Inagene updates its medication-gene association database quarterly, adding new evidence-based guidance as it becomes available. A test completed today continues to grow in clinical relevance over time.
05
A pharmacogenetic test that sits unused delivers no value. Inagene’s managed program includes dedicated account management, member communications support, and ongoing utilization tracking to ensure the right members are reached at the right time, and that program adoption translates into measurable outcomes. This is what separates a passive benefit from a program that performs.
Inagene's program is built on a foundation of peer-reviewed clinical evidence — not emerging science or proprietary claims. The pharmacogenetics behind our testing protocols has been validated across thousands of patients in published clinical trials.
increased likelihood of remission for patients with major depressive disorder when prescribing is guided by pharmacogenetics
reduction in adverse drug reactions when individual genetics guide prescribing decisions
of people carry gene variants that affect their response to at least one commonly used medication
Calian Health, a leading Canadian health services organization, piloted Inagene's pharmacogenetic testing program with 50 patients managing chronic pain and mental health conditions. The results demonstrated the real-world impact of PGx-guided prescribing on medication effectiveness, patient outcomes, and avoidable costs.
100%
of patients found a more effective treatment sooner and avoided unnecessary drug costs
98%
avoided medication side effects or had shorter absences due to lack of medication efficacy or side effects
$3,008
average per-patient savings projected over three years
3.3 years
average avoidable trial-and-error medication time per patient
Results are illustrative and may not be representative of all plan populations.
What Clinicians Are Saying
"About 80% of my patients have had to deal with trial and error in at least one or more of their medications — particularly with antidepressants, but also cholesterol, migraine, birth control, and hormone therapy. It's very prevalent."
What Plan Members Are Saying
"I sent my results to my doctor and we agreed to put me on Zoloft. I've been on it for about three months now with almost no side effects — it was a really smooth transition.
When you keep trying different antidepressants and they're not working, you almost start feeling like you're crazy, so it was really validating to see that the ones I had tried had come up as the ones that don't agree with me."
What The Media Is Saying
CAP Proficiency Testing
Health Canada Medical Device Establishment Licence #9922
ISO27001 certification
Canadian data sovereignty — all data stored and processed in Canada
Compliant with applicable privacy laws
Ready to see what Inagene can do for your organization?